This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Steris (STE) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 8.72% and 0.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong segmental performances are driving the top line for STERIS (STE).
Steris (STE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment
by Zacks Equity Research
The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental growth and bullish 2022 outlook.
Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray
by Zacks Equity Research
Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray
3 Top Medical Instruments Stocks to Counter Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most. Yet, demand for base business is on the decline with the new COVID variant disrupting the trend.
Steris (STE) Down 3.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain STERIS (STE) Stock For Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.
STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.
Steris (STE) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 8.74% and 3.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).
Here's Why You Should Add STERIS (STE) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.
Steris (STE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Steris (STE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Steris (STE) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.
STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up
by Zacks Equity Research
STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.
Steris (STE) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 17.33% and 7.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.